Concentric Analgesics, Inc.

Concentric Analgesics, Inc. is focused on developing innovative, non-opioid therapeutics for long-lasting pain relief, particularly targeting issues in cancer treatment and osteoarthritis through advanced prodrug technology. Concentric Analgesics, Inc. specializes in developing novel therapeutics for pain management.

Founded in 2014 and headquartered in San Francisco, US, the company has engaged in three deals, with the most recent completed on January 26, 2022. The company's founder, Craig Husfeld, has a history of involvement in related ventures. Recent funding includes USD 20 mn raised in a VENTURE DEBT round, contributing to a total of USD 77. 1 mn raised.

Concentric Analgesics, Inc. specializes in developing a portfolio of novel, non-opioid therapeutics tailored for long-lasting pain relief following a single local administration. The company's main product offerings are based on a unique class of TRPV1 agonist prodrugs aimed at addressing the pervasive issues associated with pain management, particularly in the context of cancer treatment and osteoarthritis. These products are designed to target pain at its source while minimizing systemic exposure, thereby reducing the risk of opioid-related adverse events.

The intended end users encompass patients experiencing moderate to severe pain, particularly those recovering from surgery or managing chronic conditions. The therapeutic solutions developed by Concentric are marketed primarily in North America and Europe, where there is a significant demand for effective pain relief alternatives to opioids. Revenue generation for Concentric Analgesics is centered around the commercialization of its innovative pain relief products. The company engages in business-to-business (B2B) transactions with healthcare providers, hospitals, and clinics, facilitating access to their therapeutics for patient treatment.

The transaction structure typically involves direct sales to these institutions, which may include bulk purchasing agreements and contracts for supply. These arrangements enable healthcare facilities to incorporate Concentric’s products into their pain management protocols. While specific pricing details for their flagship prodrugs are not disclosed, the company's focus remains on providing cost-effective solutions that reduce reliance on traditional opioid therapies, thereby positioning themselves favorably within the evolving healthcare landscape. In January 2022, Concentric Analgesics, Inc.

raised USD 20 mn in VENTURE DEBT to support its Phase 3 development activities for vocacapsaicin, its lead therapeutic candidate for post-surgical pain. The company aims to further enhance its product lineup and expand its presence in international markets, particularly targeting Europe and Asia by 2023.